Aubrey Molgaard, DNP, ARNP, FNP-BC, CDCES

December 05, 2024

Panelists discuss how teplizumab therapy can delay the onset and progression of type 1 diabetes (T1D) by preserving β-cell function and reducing the risk of developing full-blown diabetes in at-risk individuals.

December 05, 2024

Panelists discuss clinical use of teplizumab including patient selection, navigating approval processes, and managing the 14-day infusion regimen to optimize outcomes and delay the progression of type 1 diabetes.

December 04, 2024

Panelists discuss how delaying intervention between stage II and stage III T1D can result in irreversible β-cell loss, higher rates of complications, and poorer overall outcomes for patients.

December 04, 2024

Panelists discuss how understanding the stages of type 1 diabetes (T1D) progression is crucial for early intervention, with a focus on delaying disease advancement through proactive treatments like teplizumab.

December 04, 2024

Panelists discuss how delaying intervention in stage 2 T1D can lead to faster disease progression, increased risk of complications like diabetic ketoacidosis, and greater long-term burden on patient health and quality of life.

December 04, 2024

Panelists highlight the burden of type 1 diabetes including the significant physical, emotional, and financial challenges faced by patients and their families, emphasizing the need for early intervention and proactive management strategies.